Acumen Pharmaceuticals(ABOS) Newsfilter·2025-03-20 20:00Core Viewpoint - Acumen Pharmaceuticals is set to report its fourth quarter and year-end 2024 financial results on March 27, 2025, and will host a conference call for updates [1]. Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3]. - The company is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, currently in a Phase 2 clinical trial (ALTITUDE-AD) after positive Phase 1 trial results [3]. - Acumen's scientific founders have pioneered research on amyloid beta oligomers, which are recognized as early triggers of Alzheimer's disease pathology [3].